Drug Trial Radar · NCT05949333
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 7, 2023
Primary completion
Jan 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Eunseong Medical Foundation Good GANG-AN HOSPITALAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hanmi Pharmaceutical Company Limited
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia
Conditions
- Breast Neoplasms
Interventions
EflapegrastimDrug
long-acting granulocyte-colony stimulating factor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate of severe neutropenia Incidence rate of severe neutropeniaTime frame: cycle 2-5 (21 days for each cycle), 105 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Good Gang-An Hospital
Busan, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.